<DOC>
	<DOC>NCT01609023</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in combination with chemotherapy in 1st and 2nd line treatment of patients with CD20-positive C-cell chronic lymphocytic leukaemia. Data will be collected from eligible patients receiving MabThera/Rituxan according to the Summary of Product Characteristics during 6 months of treatment.</brief_summary>
	<brief_title>An Observational Study of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With CD20-Positive B-Cell Chronic Lymphocytic Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with CD20positive Bcell chronic lymphocytic leukaemia eligible for 1st line or 2nd line therapy according to the approved summary of product characteristics (SPC) Contraindications to MabThera/Rituxan therapy according to the approved SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>